In primary triple-negative (TN) breast cancer, SIGLEC7/9 expression is higher compared to estrogen receptor-positive breast cancer and SIGLEC9 was present on almost all (>90%) of the CD11b+ cells, being mostly absent on CD3+ or CD56+ cells with high SIGLEC7 expression. This evidence concerns the gene ESR1 and breast carcinoma.